Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease
Sven Schneider, Katharina Poglitsch, Christina Morgenstern, et al.
European Respiratory Journal (2022) Vol. 61, Iss. 3, pp. 2201335-2201335
Open Access | Times Cited: 21

Showing 21 citing articles:

S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023
Marek Lommatzsch, Carl-Peter Criée, Carmen C.M. de Jong, et al.
Pneumologie (2023) Vol. 77, Iss. 08, pp. 461-543
Open Access | Times Cited: 43
The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma
Kazuyuki Nakagome, Makoto Nagata
Biomolecules (2024) Vol. 14, Iss. 5, pp. 546-546
Open Access | Times Cited: 14
IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease
Chongjia C. Chen, Kathleen M. Buchheit, Pui Y. Lee, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 2, pp. 458-467.e3
Closed Access | Times Cited: 8
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence
Shiru Cai, Shenglong Xu, Yan Zhao, et al.
Allergy (2025)
Open Access | Times Cited: 1
Mechanistic and clinical updates in AERD: 2021-2022
Whitney W. Stevens, Katherine N. Cahill
Journal of Allergy and Clinical Immunology (2023) Vol. 151, Iss. 6, pp. 1448-1456
Open Access | Times Cited: 11
Asthma Phenotypes and Biomarkers
Jocelyn R. Grunwell, Anne M. Fitzpatrick
Respiratory Care (2025)
Closed Access
The effect of biological agent use on symptoms in patients diagnosed with NSAID-Exacerbated Respiratory Disease (NERD)
Hatice Çelik Tuğlu, Kurtuluş Aksu, Onur Telli, et al.
Revue française d'allergologie (2025) Vol. 65, Iss. 4, pp. 104219-104219
Closed Access
Deep immune profiling of chronic rhinosinusitis in allergic and non-allergic cohorts using mass cytometry
Fana Alem Kidane, Lena Müller, Marianne Rocha-Hasler, et al.
Clinical Immunology (2024) Vol. 262, pp. 110174-110174
Open Access | Times Cited: 3
Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?
Tanya M. Laidlaw, Andrew A. White
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 12, Iss. 1, pp. 79-84
Closed Access | Times Cited: 8
The Role of Biologics in the Treatment of Chronic Rhinosinusitis
Nora Haloob, Katerina Karamali, Claire Hopkins
BioDrugs (2023) Vol. 37, Iss. 4, pp. 477-487
Closed Access | Times Cited: 7
'Efficacy of biologics in NSAID-ERD: United airways from the nose to the bronchi'
Kathleen M. Buchheit, Elke Vandewalle, Hester Beatrice Emilie Elzinga, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 11, pp. 2917-2932
Closed Access | Times Cited: 2
Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma
Glenis Scadding, Claudia L. Gray, Diego M. Conti, et al.
Frontiers in Allergy (2024) Vol. 5
Open Access | Times Cited: 2
Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics
Irina Bobolea, Jan Hagemann, Marek Sanak, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 11, pp. 2934-2944
Open Access | Times Cited: 2
Personalized management of aspirin-exacerbated respiratory disease: From clinical presentation to therapeutic strategies
Dana Wallace
Journal of Precision Respiratory Medicine (2024) Vol. 7, Iss. 1, pp. 3-11
Open Access | Times Cited: 1
Hat die ASS-Desaktivierung in Zeiten von Biologika noch einen Stellenwert bei chronischer Rhinosinusitis mit nasaler Polyposis?
Felix Klimek, Ulrike Förster‐Ruhrmann, Jan Hagemann, et al.
HNO (2024) Vol. 72, Iss. 7, pp. 484-493
Closed Access
Dupilumab dampens mucosal type 2 response during acetylsalicylic acid challenge in N-ERD patients
Julia Eckl‐Dorna, Christina Morgenstern, Katharina Poglitsch, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody
Hiroaki Hayashi, Makoto Ishii, Yoshinori Hasegawa, et al.
Allergology International (2024)
Open Access
Dupilumab dampens mucosal type 2 response during acetylsalicylic acid challenge in N-ERD patients
Sven Schneider, Julia Eckl‐Dorna, Christina Morgenstern, et al.
Research Square (Research Square) (2024)
Closed Access
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance
Donald W. Cockcroft
European Respiratory Journal (2023) Vol. 61, Iss. 3, pp. 2202467-2202467
Closed Access
Management of Aspirin-Exacerbated Respiratory Disease
Erin K. O’Brien, Elina Jerschow, Rohit Divekar
Otolaryngologic Clinics of North America (2023) Vol. 57, Iss. 2, pp. 265-278
Closed Access
Deep immune profiling of chronic rhinosinusitis in allergic and non-allergic cohorts using mass cytometry
Fana Alem Kidane, Lena Müller, Marianne Rocha-Hasler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top